Outcomes80

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 20 of 80

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Part 1A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)	Up to approximately 367 weeks	All Treated population included all participants who received at least one dose of feladilimab.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Dose Limiting Toxicity (DLT)	Up to 28 days	DLT Evaluable Population included All Treated Population in the dose escalation phase or PK/PD cohorts, who completed the 28-day DLT observation period or experienced a DLT during the determinative period (28 days).	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters	Baseline (Day 1) and up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All treated population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 1A: Number of Participants With Dose Modifications of Feladilimab	Up to approximately 367 weeks	All treated population	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)	Up to approximately 367 weeks	All Treated population	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Dose Limiting Toxicity (DLT)	Up to 28 days	DLT Evaluable Population. As pre-specified in the protocol, only specified treatment arms were planned and hence there are 0 participants analyzed for rest of the arms.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters	Baseline (Day 1) and up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Worst Case Hematology Results Relative to Normal Range Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Worst Case Urinalysis Results Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All treated population. Only those participants with data available at specified categories have been analyzed	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Part 2A: Number of Participants With Dose Modifications of Feladilimab	Up to approximately 367 weeks	All Treated population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Part 1B: Number of Participants With Any Adverse Event(s) (AEs) and Serious Adverse Event(s) (SAEs)	Up to approximately 367 weeks	All Treated population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Clinical Chemistry Parameters	Baseline (Day 1) and up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Part 1B: Number of Participants With Worst Case Chemistry Results Relative to Normal Range Post-Baseline Relative to Baseline	Up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Part 1B: Number of Participants With Worst-case Grade Change From Baseline in Hematology Parameters	Baseline (Day 1) and up to approximately 367 weeks	All Treated Population. Only those participants with data available at specified categories have been analyzed.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02723955/outcomes

API reference For AI assistants

Outcomes80

Sources 3

Read this list from software.